POTASSIUM ACETATE INJECTION USP 39.2 % — DIN 02362597
POTASSIUM ACETATE : 39.2 % · OMEGA LABORATORIES LIMITED · LIQUID · wholesale supply in Canada
Health Canada status: MARKETED
What is POTASSIUM ACETATE INJECTION USP?
POTASSIUM ACETATE INJECTION USP 39.2 % contains POTASSIUM ACETATE : 39.2 %. It is listed in the Health Canada Drug Product Database under DIN 02362597, held by OMEGA LABORATORIES LIMITED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 10-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POTASSIUM ACETATE INJECTION USP used for?
Replacement and maintenance of normokalemia when a source of acetate is also required or when potassium chloride cannot be used.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Potassium Acetate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Potassium Acetate, across 5 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| OMEGA LABORATORIES LIMITED | 1 | 1 | POTASSIUM ACETATE INJECTION USP | Sourceable in Canada |
| ABBOTT LABORATORIES, LIMITED | 1 | 0 | POTASSIUM ACETATE INJ 2MEQ/ML | No marketed DIN |
| FRESENIUS KABI CANADA LTD | 1 | 0 | POTASSIUM ACETATE INJECTION | No marketed DIN |
| LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | 1 | 0 | POTASSIUM ACETATE INJ 392MG/ML USP | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | POTASSIUM ACETATE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 39.2 % |
|---|---|
| Dosage form | LIQUID |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Boxes of 10 vials x 50 mL. Flip-top vials. Stopper not made with natural rubber latex. |
| Storage | Store between 15 and 30°C. Do not freeze. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Potassium Acetate |
|---|---|
| ATC code | B05XA17 |
| AHFS class | 40:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02362597 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2362597 |
| Brand name | POTASSIUM ACETATE INJECTION USP |
| Generic / active ingredient | POTASSIUM ACETATE : 39.2 % |
| Market authorization holder | OMEGA LABORATORIES LIMITED |
| Health Canada schedule | Ethical |
| ATC code | B05XA17 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XA |
| Current status | MARKETED |
| Status date | 10-Oct-2025 |
| Original market date | 2016-07-18 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered i.v. only after dilution. Dose and rate depend on patient needs. Monitor ECG and serum potassium. Not for direct injection. Use immediately after dilution.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hyperkalemia; diseases or conditions that predispose to hyperkalemia.
Warnings and precautions
Must be diluted. High/low potassium is toxic. Infusion rate >10 mmol/hour requires cardiac monitoring. Caution in cardiac/renal disease and metabolic/respiratory alkalosis.
Is Potassium Acetate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| POTASSIUM ACETATE | 392 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 00780650 |
| POTASSIUM ACETATE INJ 2MEQ/ML | 2 mEq | SOLUTION | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | 00613444 |
| POTASSIUM ACETATE INJ 392MG/ML USP | 392 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01944894 |
| POTASSIUM ACETATE INJECTION | 392 MG | SOLUTION | FRESENIUS KABI CANADA LTD | DORMANT | 02139553 |
2 · Same class — other molecules in ATC B05XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sodium Chloride | 0.45% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION · 0.9% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION, USP · +23 more | 37 | 11 | Yes |
| Potassium Chloride | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) · POTASSIUM CHLORIDE INJ 149MG/ML USP · +7 more | 17 | 7 | Yes |
| Sodium Bicarbonate | SODIUM BICARBONATE 5% INJ 50MG/ML USP · SODIUM BICARBONATE 5% INJ 5GM/100ML USP · SODIUM BICARBONATE INJ 4.2% · SODIUM BICARBONATE INJ 7.5% · +6 more | 18 | 5 | Yes |
| Electrolytes In Comb With Other Drugs | ADDNUTRIV · MICRO +4 REGULAR STRENGTH · MICRO PLUS 4 CONCENTRATE · MICRO PLUS 5 CONCENTRATE · +10 more | 14 | 5 | Yes |
| Calcium Gluconate | 2% CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE INJECTION USP 10% · CALCIUM GLUCONATE INJECTION, USP 10% | 5 | 5 | Yes |
| Magnesium Sulphate | MAGNESIUM SULFATE IN WATER FOR INJECTION · MAGNESIUM SULFATE INJ 50% · MAGNESIUM SULFATE INJECTION 50% USP · MAGNESIUM SULFATE INJECTION BP · +3 more | 9 | 4 | Yes |
| Zinc Sulfate | MICRO ZN · ZINC SULFATE INJECTION, USP | 4 | 4 | Yes |
| Potassium Phos Incl Comb W/0th Pot. Salts | POTASSIUM PHOSPHATE INJ 3MMP/ML · POTASSIUM PHOSPHATE MONOBASIC INJECTION · POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATES INJ · +1 more | 5 | 3 | Yes |
| Calcium Chloride | CALCIJECT INJ 100MG/ML · CALCIUM CHLORIDE INJECTION BP · CALCIUM CHLORIDE INJECTION USP · CALCIUM-35 0.25 - 10 · +1 more | 5 | 2 | Yes |
| Sodium Acetate | 16.4% SODIUM ACETATE INJECTION, USP · SODIUM ACETATE INJ 328MG/ML USP · SODIUM ACETATE INJECTION USP · SODIUM ACETATE INJECTION, USP | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XC | Vitamins | 9 | 2 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.